VPA-985, a nonpeptide orally active and selective vasopressin V2 receptor antagonist

被引：0

作者：

Chan, PS ^{[1
]}

Coupet, J ^{[1
]}

Park, HC ^{[1
]}

Lai, F ^{[1
]}

Hartupee, D ^{[1
]}

Cervoni, P ^{[1
]}

Dusza, JP ^{[1
]}

Albright, JD ^{[1
]}

Ru, X ^{[1
]}

Mazandarani, H ^{[1
]}

Tanikella, T ^{[1
]}

Shepherd, C ^{[1
]}

Ochalski, L ^{[1
]}

Bailey, T ^{[1
]}

Lock, TYW ^{[1
]}

Ning, XP ^{[1
]}

Taylor, JR ^{[1
]}

Spinelli, W ^{[1
]}

机构：

[1] Wyeth Ayerst Res, Princeton, NJ 08543 USA

来源：

VASOPRESSIN AND OXYTOCIN: MOLECULAR, CELLULAR, AND CLINICAL ADVANCES | 1998年 / 449卷

关键词：

D O I：

暂无

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

引用

页码：439 / 443

页数：5

共 50 条

[1] OPC-31260 - A NONPEPTIDE ORALLY ACTIVE V2 VASOPRESSIN RECEPTOR ANTAGONIST
BURRELL, LM
PHILLIPS, PA
STEPHENSON, J
RISVANIS, J
JOHNSTON, CI
JOURNAL OF ENDOCRINOLOGY, 1992, 135 : P56 - P56
[2] Synthesis and characterization of orally active nonpeptide arginine vasopressin V2 receptor antagonist.
Ohkawa, T
Setoi, H
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1997, 213 : 104 - MEDI
[3] Synthesis and characterization of orally active nonpeptide vasopressin V2 receptor antagonists
Ohkawa, T
Zenkoh, T
Tomita, M
Hosogai, N
Hemmi, K
Tanaka, H
Setoi, H
CHEMICAL & PHARMACEUTICAL BULLETIN, 1999, 47 (04) : 501 - 510
[4] Pharmacodynamic (PD) effects of a novel, non-peptide, V2 receptor antagonist, VPA-985 (VPA), given with hydrochlorothiazide (H).
Patat, A
Ellis-Grosse, EJ
Orczyk, G
Gandon, JM
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2000, 67 (02) : 110 - 110
[5] Pharmacokinetics and pharmacodynamics of a novel vasopressin receptor antagonist, VPA-985, in healthy subjects.
Muralidharan, G
Meng, X
DeCleene, SA
Cevallos, WH
Fruncillo, R
Hicks, D
Orczyk, GP
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1999, 65 (02) : 189 - 189
[6] VNA-932:: First orally active, nonpeptide, vasopressin V2 receptor selective agonist.
Dusza, JP
Caggiano, TJ
Ashwell, MA
Bagli, JF
Albright, JD
Delos Santos, EG
Du, XM
Failli, AA
Hodgkin, EE
Molinari, A
Shumsky, JS
Steffan, RJ
Trybulski, EJ
Williams, DK
Chan, PS
Park, CH
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2000, 219 : U38 - U39
[7] VPA-985, an orally active vasopressin receptor antagonist improves hyponatremia in patients with cirrhosis - A double-blind placebo controlled multicenter trial.
Gerbes, AL
Guelberg, V
Decaux, G
Gross, P
Massien, C
Djian, J
HEPATOLOGY, 1999, 30 (04) : 419A - 419A
[8] Difference in solute excretion during correction of hyponatremic patients with cirrhosis or syndrome of inappropriate secretion of antidiuretic hormone by oral vasopressin V2 receptor antagonist VPA-985
Decaux, G
JOURNAL OF LABORATORY AND CLINICAL MEDICINE, 2001, 138 (01): : 18 - 21
[9] Nonpeptide vasopressin receptor antagonists:: development of selective and orally active V1a, V2 and V1b receptor ligands
Serradeil-Le Gal, C
Wagnon, J
Valette, G
Garcia, G
Pascal, M
Maffrand, JP
Le Fur, G
VASOPRESSIN AND OXYTOCIN: FROM GENES TO CLINICAL APPLICATIONS, 2002, 139 : 197 - 210
[10] Aquaretic effect of a potent, orally active, nonpeptide V2 antagonist in cirrhosis
Inoue, T
Ohnishi, A
Matsuo, A
Kawai, B
Harada, M
Okada, K
Yamamura, Y
Tanaka, T
HEPATOLOGY, 1996, 23 (01) : T26 - T26

← 1 2 3 4 5 →